Whether a gender difference exists in the prevalence of POAG has been controversial. Numerous studies have reported that the prevalence of OAG is higher in men,
1 10 12 48 others have reported a higher prevalence in women,
6 31 and yet others have reported no gender difference in prevalence.
2 3 4 5 9 11 49 51 Heterogeneity in the reporting of these gender effects may be explained by lack of power, with insufficient numbers of OAG cases within individual studies to detect consistent gender differences together with appropriate adjustment for age. If, for example, the true prevalence of OAG is 1.5% in women and 2.2% in men within a given age group (based on the findings from the present study), the required sample size for an individual study would have to be approximately 16,500 to detect a statistically significant difference at the 5% level (i.e.,
P = 0.05) and 90% power. There is no single study of this size. Pooling data from different studies allowed the gender effect to be determined with greater statistical certainty. Data from 61,267 subjects (including 1355 OAG cases) suggests that OAG prevalence in men is approximately 1.4 times that in women (adjusted for age, racial group, publication year, and survey methods); this effect was remarkably consistent across the three racial groups. This finding disagrees with a previous meta-analysis
14 that did not find a difference in the prevalence of OAG between men and women after controlling for age in white, black, or Hispanic populations.
14 However, this pooled analysis was based on one study in a black population (
n = 2395) and one study in an Hispanic population (
n = 4773) and was probably underpowered to detect gender difference in these two racial groups. Although the analysis was probably sufficiently powered to answer this question for the six studies in white populations (
n = 22,556), investigators had access to additional unpublished data for these studies by gender that were not in the original study publications and were therefore able to perform an individual patient data meta-analysis. Only two of the studies included in that review had published data by gender; therefore, the other 4 studies were not included in our gender analyses. Differences can arise between meta-analyses that are performed using published estimates and those based on individual patient data because of differences in the accuracy or structure of the data, analytical approach, and studies included. An individual level meta-analysis allows a more flexible approach to the analyses and is preferable if raw data can be obtained for all relevant studies. If, however, raw data can only be obtained for a limited number of all relevant studies identified, the review may not be representative and the results may be biased. In the current international review, it is likely that it would not have been possible to obtain the raw data for a considerable proportion of the studies, especially as some were conducted many years ago. We therefore chose to undertake a meta-analysis of published data and estimates. The estimated OR in white populations for males compared with females from the previous review was 0.97 (95% CI, 0.79–1.20). We can use this result from the six studies in white populations as a “Bayesian prior” and combine it with our review data (excluding the two studies from our data to avoid double counting). The OR for men compared with women then becomes 1.23 (95% CrI, 1.06–1.42), indicating that OAG prevalence is estimated to be 23% higher in men than in women. This is the best available estimate, and it includes their data
14 and our review data appropriately combined, and the estimate is consistent with a recent very large study
52 looking at the prevalence of glaucoma treatment in the United Kingdom, where the OR of treatment for glaucoma in men compared with women was 1.24 (95% CI, 1.19–1.28).
52 A biological hypothesis for a gender difference in prevalence remains unclear and may reflect differences in environmental exposure between men and women; perhaps similar parallels can be drawn with well-known gender differences in other noncommunicable diseases such as cardiovascular disease.